

AnQuery

WORKED EXAMPLE

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial. **Title:** Effect of Neladenoson Bialanate on Exercise Capacity Among Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial.

Objective: To determine whether neladenoson improves exercise capacity, physical activity, cardiac biomarkers, and quality of life in patients with HFpEF and to find the optimal dose.

Year: 2019

Source: Journal of the American Medical Association

Link: https://doi.org/10.1001/jama.2019.6717

Protocol: https://clinicaltrials.gov/ct2/show/NCT03098979

Clinical Area: Cardiology

Sample Size Section in Paper/Protocol:

"Based on the assumption of a maximum effect for an absolute increase in 6-minute walk test distance of **40 m for a particular dose** of neladenoson bialanate, an absolute increase of **0 m with placebo**, and an **SD of 80 m**, an **overall sample size of 216** randomized patients (using a **1:2:2:2:2:3 randomization ratio** corresponding to the 5 neladenoson doses and placebo) was required to ensure a **minimum power of 80%** to detect the presence of a dose response."

"Patients (were) randomized to receive neladenoson **(5 mg, 10 mg, 20 mg, 30 mg, or 40 mg**) or placebo"

"A multiple comparison procedure with 5 modelling techniques (**linear**, **Emax**, **2 variations of sigmoidal Emax**, and **quadratic**) was used to evaluate diverse dose-response profiles."

"All statistical tests were performed at a **significance level of .05**. Significance testing was **1-sided**."

Summary of Necessary Parameter Estimates for Sample Size Calculation

Parameter	Value
Significance Level (1-sided)	0.05
Number of Doses	6 (0mg, 5mg, 10mg, 20mg, 30mg, 40mg)
Sample Size Ratio per Dose	3:1:2:2:2:2
Number of Models	5 (Linear, Emax, Sigmoid Emax (x2), Quadratic)
Power Criterion	Minimum
Placebo Effect, δ_0	0
Max Treatment Effect, δ_1	40
Standard Deviation, σ	80
Power	80%

Parameter Values for Dose-Response Models

Model (Table 10-1 in Clinical Study Protocol)	Parameter Values
Linear: $f(d) = d$	No input required
Emax: $f(d) = \frac{41.25d}{1.25+d}$	θ ₁ = 1.25
Sigmoid Emax 1: $f(d) = \frac{40.1d^{-4}}{9^{-4}+d^{-4}}$	$\theta_1 = 9, \theta_2 = 4$
Sigmoid Emax 2: $f(d) = \frac{45d^{-3}}{20^{-3}+d^{-3}}$	θ ₁ = 20, θ ₂ = 3
Quadratic: $f(d) = 2.667d - 0.044d^{-2}$	θ ₁ = -0.044/2.667

Step 1:

Select the MGT5 Multiple Comparisons Procedure - Modelling for Continuous Outcome (Common Variance) (MCP-Mod) table from the Study Design Pane.

This can be done **using the radio buttons** or alternatively, you can **use the search bar** at the end of the Select Test Design & Goal window.

Q	Selec	ct Test	- • ×
Design	Goals	No. of Groups	Analysis Methods
Fixed	Means	One Group	✓ Inequality
Bayesian	Proportions	Paired	Equivalence
✓ Adaptive	Survival	Cross-over	Non-inferiority
	Counts	Two	Intervals
	Agreement	✓ > 2	
	Regression	Hierarchical	
MGT5 Multiple Comparis	ons Procedure - Modelling for Con	tinuous Outcome (Common Varian	ce) (MCP-Mod)
MGT6 Multiple Arms Mul	tiple Stage (MaMs) Group Sequent	ial Design for Means	
MGT7 Multiple Comparis	ons Procedure - Modelling for Pois	son Rates (MCP-Mod)	
MGT8 Multiple Comparis	ons Procedure - Modelling for Neg	ative Binomial Rates (MCP-Mod)	
Type here to search all tests			Clear Search
			OK Cancel

Step 2:

Enter the parameter values in the main table for the sample size calculation taken from the study description.

First, complete the **main table**. Note: Minimum power criterion implies that the total power of the test will be equal to the minimum power of the candidate models.

An optional random seed is also specified here to allow replicable results.

-	Multiple Co	nperison: + +		
ИG	TS-1 / Multiple Compariso	ns Procedure - M	odelling (MC)	P-Mod)
		1	2	3
-	ut Significance Level, e	0.100		
	or 2 Sided Text?	2	2	2
14	umber of Down, D	5		
	umber of Models, M	4		
P1	wer Oriterion	Mean	Mean	Mean
m	acebo Effect, Ba	0.000		
1.00	as Treatment Office, &c	3.000		
194	andard Devlation, #	8.100		
P1	ment (NJ)			
6	Minal Value, Ta			
1.	androm Sand	9876		
1.64	rual Sumpler Size, N			

Next, complete the Dose Levels and Candidate Models **side table.** The weighting is used to distribute the sample size across the dose groups as specified.

	Doors	Weighting		1	2	3	4	5
1	0.000	3:000	Model	Linear	6max (80%0)	Signoid lines (025)	Signoid lines (EDS)	Quedratic (f)
2	5.000	1.000	Parameter 1. 0.		1,250	9.000	20.000	-0.016497907
	10.000	2:000	Parameter 2, 0,			4.000	3.000	
4	25.000	2,000	Parameter 3, 0,					
5	36.000	2,000	Model Pewer					
+ 6	40.000	2,000	Placebo Dose, els	0.000	0.000	0.000	0.000	0.000
			Max Effect Done, du	40.000	40.000	40.000	40.000	40.000
			10					
			Emax					

Step 3:

Enter the required **power** in the main table and the **sample size** and **candidate model powers** will be calculated.

The analysis calculates a total sample size of 216 with 54 subjects in the placebo group, 18 subjects in the 5mg dose group and 36 subjects in each of the remaining dose groups.

A minimum power of 80.31% was achieved with this sample size. The per-model powers ranged from 80.31% (Sigmoid Emax model with parameters 20 & 3) to 91.79% (Sigmoid Emax model with parameters 9 & 4).

The maximum effect dose was the 40mg dose for the Linear, Emax and Sigmoid Emax models while the Quadratic model achieved the maximum effect at the 30mg dose.

This sample size is consistent with the source paper.

			1	2 1		4	5	1 7		9
lest Signific	cance Level, e		250							
or 2 Sided	d Test?		8	1 1		1	1	1 1	1	1
lumber of 1	Orses, D		6							
uniter of 1	Models, M		5							
lower Criter	nion	Min	mum	Mari Me	an h	fean	Mean M	an Mean	Mean	Mean
lacebo Effe	lect, the	0	000							
for Deater	next Effect, 8.	-40	000							
itandard De	eviation, a	80	000							
Nomer (No			131							
Istal Sampl	Ar Size, N	2	16							
Critical Value	at, Ta	10	858							
Rendom Ser	and .		121							
	an ind smale in	¢								
eluine tre 1 GT55-1	required sample size	e interest						_		
GTSS-1	required sample size	c		11		1	2		4	3
GTSS-1	required sample size (2) Plot Door Rep Oroan 0.000	4 Weighting 1.000	. 34.300	Made		1 Deser	2 (nas (220)	3 Sproof Inst (175)	4 Septed lines (10%)	5 Quadratic
6755-1	Programmed sample stor	4 01um 1.000 1.000	* 54.300 10.300	Model Parameter 1, 0,		1 Linuar 1.000	2 (mar (2010) 1.210	3 Signat fina (2010)- 6-000	4 Tapmaid (1940, 2000	S Quadratic -0006
di Jane Tre GT55-1 1 2 3	Inguined samples size Mat Down Resp 0.000 1.000 10.000	4 Weighting 2.000 2.000	* 54.300 74.300 34.300	Madel Parameter 1, 6, Parameter 2, 6,		1 Unsar 1.000	2 (mar (570) 1,210	3 Signal Enas (8210)- 9.002 4.005	4 Topmood Onnae (1014) 20000 30000	3 Guadratic 4016 2.540
GTSS-1	esquired sample size Port Door Rep 0.000 5.000 10.000 20.000	4 00005 1.000 1.000 2.000 2.000	* 54200 31300 36300 36300	Model Parameter 1, 6: Parameter 2, 6:		1 Linear 1.000	2 8ma (2010) 1,210	3 Topmool Smar (8750,- 8-000 4-000	4 Topmud Grass (1000 20000 3.000	3 Qualitatic 0.016 0.016 0.016
GTSS-1	required sample size (************************************	4 Weighting 3.000 1.000 2.000 2.000 2.000	* 54300 76300 24300 24300 34300	Model Parameter 1.45 Parameter 2.45 Parameter 1.45 Model Press		1 Unsur 1.000 41.019	2 Smar (2050) 1/200 MAR5	3 Topmool Enex (8070), 9 5070 4 2000 91,752	4 Ispesiel (mas (200), 2000 3000 85.008	8 Guadratic -0.016 -0.046 -0.046 -0.046
duon Te - GTSS-1 1 2 3 4 5 6	required sample size (2) Plot Doos Rep 0.000 10.000 10.000 20.000 30.000 40.000	4	* 5438 1030 3638 3638 3638	Madel Parameter 1. 9, Parameter 3. 9, Parameter 3. 9, Model Param Pacche Dess. 6		1 Unear 1.000 81.015 0.000	2 Email (2010) 1,210 44,475 6,000	3 Synut Ina (ISS), 800 400 91/32 600	4 Topmoid (Imas (2000) 3.000 86.004 86.00	8 Cauditatic -0.014 -0.044 -0.044 -0.044 -0.049
6755-1 1 2 3 4 5 6	Tempired sample size 20 Plot Doese Resp 6:000 5:000 10:000 20:000 30:000 40:000	4 Weighting 1.000 1.000 2.000 2.000 2.000 2.000	* 5430 5430 5430 5430 5430 5430 5430 5430	Madal Prasmeter 1, 4h Prasmeter 2, 4h Prasmeter 3, 4h Madal Preser Packo Dona, 4h Mas Histo Dona		1 Uniar 1000 41470 4000	2 8na (1710) 1,250 46,675 6,000 46,000	3 Бреной Глас (101), 500 4.000 91,782 6.000 4.000	4 10pmsl 8010,- 20000 3.000 883.000 6000 40.000	5 Guellele 2540 0.004 0.000 0.000 0.000
GTSS-1 I J J J J GTSS-1 I J J J J J J J J J J J J J J J J J J	regard tample size 20 Part Door Rep 0.000 1.000 10.000 20.000 40.000 40.000	4 Weighting 1.000 2.000 2.000 2.000 2.000 2.000 2.000	* 54.500 54.500 54.500 54.500 54.500	Madel Parameter 1, 49, Parameter 3, 49, Parameter 3, 49, Model Parel Pacobo Dosa, 4 Model Parel Pacobo Dosa, 6 Mas Histi Tosa		1 Unior 1000 40.000 40.000	2 8ma (5733 1,230 84,473 6,000 46,000 6,000	3 5gmail Sna (50%) 4.00 4.00 4.00 4.00 4.00 0.00	4 Topmold Umas 80000,- 202000 3.000 0.000 4.0000 6.000 6.000	5 Quadratic 40206 -0.044 80.000 -0.000 -0.000 -0.000 -0.000 -0.000

Output Statement:

"A total sample size of 216 is required to ensure a minimum power of 80.31% for an MCP-Mod analysis rejecting the null hypothesis of no difference between doses using the multiple comparisons procedure (MCP) assuming a placebo dose-response effect of 0, a maximum dose-response effect (in the dose range) of 40 and a common (residual) standard deviation of 80 per dose and one-sided family-wise error rate of 0.05, corresponding to critical multivariate t-statistic of 1.958.

This analysis assumed 6 doses with the following sample sizes per dose:

Doses: 0, 5, 10, 20, 30, 40 Sample Size: 54, 18, 36, 36, 36, 36

The following 5 models (including input parameters) were evaluated in this MCP-Mod analysis and found to have the following per-model power:

Linear: 81.07% Emax (ED50): 1.25, 88.87% Sigmoid Emax (ED50, h): 9, 4, 91.79% Sigmoid Emax (ED50, h): 20, 3, 80.31% Quadratic (δ): -0.016, 86.91%"

The output statement appears at the bottom of nQuery. This can be printed or copy and pasted into any document.



O	utput	*	×
	A total sample size of 216 is required to ensure a minimum power of 80.31% for an MCP-Mod analysis rejecting the null hypothesis of no difference between does using the multiple comparisons procedure (MCP) assuming a placebo doverseponse effect of 0, a maximum dose-response effect (in the dose range) of 40 and a common (residual) standard deviation of 80 per dose and one-sided family-wise error rate of 0.05, corresponding to critical multivariate t-statistic of 1.38	g	
	This analysis assumed 6 doses with the following sample sizes per dose:		
	Doses: 0, 5, 10, 20, 30, 40 Sample Size: 54, 18, 36, 36, 36, 36		
	The following 5 models (including input parameters) were evaluated in this MCP-Mod analysis and found to have the following per-model power:		
	Likas: 81.07% Emar(EDS): 1.2.8.88.87% Sigmoid Emar(EDS). 1:2.9.8.8.1% Ggund Emar(EDS). 1:2.0.8.0.31% Quadratic (8):-0.016, 65.91%		
	0	ľ	

How the output statement appears in nQuery.

Step 4:

nQuery can also be used to plot the dose responses for each model. To generate these plots, click on the "Plot Dose Responses" button on top of the side table.

MGTSS-1 Lt Put Dear Regionale

